Skip to main content
. 2021 Dec 1;40:377. doi: 10.1186/s13046-021-02183-3

Fig. 4.

Fig. 4

Depletion of SNHG1 enhances the efficacy of sorafenib to suppress sorafenib-resistant HCC tumors in vivo. a Animal experimental schedule was described as in Materials and Methods. b The size (mm3) of tumors was recorded. c and d Tumors harvested at the end of experiments were weighed (c) and photographed (d). e Tissue homogenates were Western blotted. The density of each band was normalized to β-actin. f Representative images of tumor sections were immunostained with an anti-Ki67 Ab and TUNEL. g Proliferation index (%) and h apoptosis index (%) were quantified. “*” (P < 0.05) and “**” (P < 0.001) indicate a significant difference from controls. “ϕ” (P < 0.05) and “ϕϕ” (P < 0.001) indicate a significant difference